Medigene AG is a biotechnology company that specializes in the development and commercialization of immunotherapies for the treatment of cancer. The company is committed to improving the lives of patients by focusing on innovative research and development. Medigene AG's corporate philosophy is based on scientific excellence, collaboration, and dedication to achieving meaningful breakthroughs in immune-oncology. By leveraging cutting-edge technologies and a deep understanding of the immune system, Medigene AG strives to develop targeted therapies that provide safe and effective solutions for patients suffering from various types of cancer.

Medigene AG is primarily present in Germany and the United States.

Medigene AG, a well-established biotechnology company, has achieved several significant milestones. Notably, Medigene successfully entered into a collaboration agreement with bluebird bio, a leading gene therapy company, to develop T-cell receptor-modified T cells (TCR-Ts) for cancer immunotherapy. This partnership aims to advance next-generation therapies for solid tumors and hematological malignancies. Additionally, Medigene's proprietary technology platform, TCR Bispecifics, has demonstrated promising results in preclinical studies, showing potential for enhanced tumor targeting and efficacy. The company has also secured various financing agreements, enabling further research and development. Medigene AG remains committed to advancing innovative immunotherapies and improving the lives of patients with cancer.

Medigene AG is a biotechnology company based in Germany. It was founded in 1994 and has since focused on the development of immunotherapy treatments for cancer. Medigene AG has a strong scientific background and expertise in T cell receptor (TCR) technologies. The company's innovative approach involves the identification and use of specific TCRs to stimulate the body's immune system to target cancer cells. Medigene AG has been actively involved in research collaborations and has a diverse pipeline of therapies in development, including personalized TCR therapies. This dedication to advancing immunotherapies makes Medigene AG an important player in the field of cancer treatment.

The main competitors of Medigene AG in the market include companies such as Inovio Pharmaceuticals, Inc., Adaptimmune Therapeutics plc, and Immatics Biotechnologies GmbH.

Medigene AG is primarily active in the biotechnology industry.

Medigene AG is a biotechnology company with a robust and innovative business model. They focus on the development and commercialization of personalized immunotherapies for the treatment of cancer. Medigene utilizes cutting-edge technologies to identify and stimulate the body's immune system to fight against cancer cells, offering promising potential for better patient outcomes. Their extensive expertise in immunotherapy and clinical research enables Medigene AG to advance novel therapeutic approaches, aiming to enhance the quality of life for cancer patients worldwide. With its strategic partnerships and a strong pipeline, Medigene AG is dedicated to revolutionizing cancer treatment through personalized medicine.

De Medigene K/W is -7,01.

De Medigene KUV is 2,11.

De AlleAktien Kwaliteitsscore voor Medigene is 3/10.

De verwachte Medigene omzet is 10,81 mln. EUR.

De verwachte Medigene winst is -3,25 mln. EUR.

Medigene AG is a leading biopharmaceutical company based in Martinsried near Munich, specializing in the development of innovative therapeutics for the treatment of cancer and other immune system disorders. The company's business model is based on a wide range of products targeting various therapeutic approaches, supported by a robust platform technology that enables the rapid and targeted development of new treatment options. Medigene's core strategy is focused on the research and development of T-cell-based immunotherapies for cancer treatment, utilizing genetically modified T-cells to target and destroy cancer cells without harming healthy cells and tissues. The company also focuses on the development of antibodies for cancer treatment and utilizes a diverse platform technology to efficiently develop new therapy options. Medigene has a strong pipeline of preclinical and clinical projects in various stages of development, and collaborates extensively with other companies and research institutions to access the latest technologies and research findings. Overall, Medigene is a significant player in the biotechnology industry, with an innovative business and research approach, a broad technological platform, and a strong financial foundation to continue expanding its research and development efforts and enter new markets.

Medigene keert een dividend van 0 EUR uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Medigene of het bedrijf keert geen dividend uit.

De ISIN van Medigene is DE000A1X3W00.

Het WKN van Medigene is A1X3W0.

De ticker van Medigene is MDG1.DE.

Binnen de laatste 12 maanden betaalde Medigene een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Medigene naar verwachting een dividend van 0 EUR betalen.

De dividendrendement van Medigene is momenteel .

Medigene betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Medigene betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 EUR verwacht. Dit komt overeen met een dividendrendement van 0 %.

Medigene wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Medigene van 9-9-2024 ter hoogte van 0 EUR te ontvangen, moest je het aandeel voor de ex-datum op 9-9-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 9-9-2024.

In het jaar 2023 heeft Medigene 0 EUR aan dividenden uitgekeerd.

De dividenden van Medigene worden in EUR uitgekeerd.